Graft vs host disease
Drug research and approvals for graft vs host disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 203 studies of graft vs host disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 24 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 203
- Trials authorized in Canada: 24
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 203 recruiting on ClinicalTrials.gov ↗- Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host DiseaseNCT07733141 · Not applicable · City of Hope Medical Center · starts Mar 1, 2027
- Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) PopulationNCT06995521 · Phase 2 · Sung Won Choi · starts Dec 1, 2026
- Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic…NCT07235501 · Not reported · City of Hope Medical Center · starts Nov 1, 2026
- A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)NCT07913672 · Phase 1 · Memorial Sloan Kettering Cancer Center · starts Oct 27, 2026
- A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged…NCT07771439 · Phase 3 · Sanofi · starts Oct 12, 2026
- Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell…NCT07193420 · Phase 3 · Assistance Publique - Hôpitaux de Paris · starts Sep 29, 2026
- A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing…NCT07350057 · Phase 1 · Shanghai Jiao Tong University School of Medicine · starts Sep 28, 2026
- FMT for Pediatric SR-aGVHDNCT07602751 · Phase 1 / Phase 2 · Bambino Gesù Hospital and Research Institute · starts Sep 17, 2026
- GMPA Versus PPI for Gastric Protection and aGVHD RiskNCT07791849 · Not applicable · First Affiliated Hospital of Zhejiang University · starts Sep 15, 2026
- Study of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD)NCT07776210 · Phase 3 · Regenerative Ocular Immunobiologics LLC · starts Sep 8, 2026
Trials Authorized in Canada
The 10 newest of 24; search them all in Canada trials| Jul 16, 2025 | An open-label, phase 1/2, multicenter study of belumosudil in children aged 1 to <18 years requiring systemic treatment for active moderate-to-severe chronic…BELUMOSUDIL (SAR445761) | SANOFI-AVENTIS CANADA INC | Pending |
| Sep 25, 2024 | A phase 3, randomized, double-blind, placebo-controlled study of axatilimab and corticosteroids as initial treatment for chronic graft versus-host diseaseAXATILIMAB | Incyte Corporation | Ongoing |
| Jun 27, 2024 | An open label, multi-center, phase IV rollover protocol for patients who have completed a prior global novartis or incyte sponsored ruxolitinib (inc424) study…RUXOLITINIB (INC424) | Novartis Pharmaceuticals Corporation | Ongoing |
| May 29, 2024 | A phase 2, open-label, randomized, multicenter study to evaluate the safety and efficacy of axatilimab in combination with ruxolitinib in participants with…AXATILIMAB/ RUXOLITINIB | Incyte Corporation | Ongoing |
| Oct 26, 2023 | A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in…BELUMOSUDIL (SAR445761) | SANOFI-AVENTIS CANADA INC | Ongoing |
| Aug 4, 2023 | Serial response and biomarker-guided steroid taper for children with gvhdPREDNISONE | THE HOSPITAL FOR SICK CHILDREN | Closed |
| May 1, 2023 | A phase Ib, open-label, randomized, dose-finding, multicenter study to evaluate the safety, pharmacokinetics, and efficacy of gdc-8264 in combination with…RO7288817 (GDC-8264) | Roche | Closed |
| Mar 17, 2022 | A phase 3, randomized, double-blind, placebo- controlled multicenter study of itolizumab in combination with corticosteroids for the initial treatment of acute…ITOLIZUMAB | EQUILLIUM, INC. | Ongoing |
| Mar 4, 2021 | A randomized, open-label phase II clinical trial comparing durable overall response rate (dor) at 56 days in patients with steroid-resistant severe acute gvhd…HUMAN PLACENTA DERIVED DECIDUAL STROMAL CELLS (DSC) | UNIVERSITY HEALTH NETWORK | Ongoing |
| Dec 18, 2020 | A phase Ib/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of eq001 in subjects with newly diagnosed…EQ001 (ITOLIZUMAB (BMAB 600)) / PREDNISONE | EQUILLIUM, INC. | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Sep 15, 2010 | MultistemProphylaxis of graft vs host disease | Athersys, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Mar 24, 2026 | Rezurockbelumosudil · orphan | Sanofi Winthrop Industrie | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA